Ask AI

Key Studies in Breast Cancer: Independent Conference Coverage of the 2026 ASCO Annual Meeting

Conference Coverage Text Module
Conference Coverage Text Module Start Activity
This activity is available for 1.00 CME/CE credit(s).

Released: September 02, 2026

Expiration: March 01, 2027

See Activity Collection

This activity reviews emerging and practice-informing clinical trial data across early and advanced breast cancer, with a focus on biomarker-guided treatment selection, endocrine resistance, targeted therapy combinations, and antibody–drug conjugates (ADCs). It examines recent evidence from OPTIMA, NATALEE, SERENA-6, ELEVATE, PIKALO-1, ASCENT-04 and -03, and TROPION-Breast02 presented at the 2026 ASCO Annual Meeting, including efficacy, safety, patient-reported outcomes, genomic and ctDNA biomarkers, and treatment-sequencing considerations. The clinically relevant content contains data that may help learners determine when chemotherapy can be safely omitted, when molecular findings should prompt a change in therapy, how to incorporate newer targeted agents and ADCs, and how to individualize treatment choices based on disease subtype, genomic risk, prior therapy, and toxicity profiles.

Breast Cancer ASCO 2026

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with breast cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A patient with previously untreated, unresectable locally advanced triple-negative breast cancer (TNBC) has a PD-L1 combined positive score (CPS) of 15 and is a candidate for pembrolizumab. Which TROP-2–directed regimen is approved by the FDA for first-line treatment in this setting?

4.

In the ASCO 2026 ELEVATE cohort reported by McHayleh and colleagues, which targeted agent was combined with elacestrant and showed preliminary activity in previously treated estrogen receptor (ER)–positive/HER2-negative advanced breast cancer (ABC) with PI3K/AKT pathway alterations?

5.

Which finding was reported from PIKALO-1 with investigational tersolisib plus endocrine therapy (ET) with or without a CDK4/6 inhibitor in PIK3CA-mutant hormone receptor–positive/HER2-negative ABC?